Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2516)	5/3/2010 10:27:13 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

AEZS also is up for 2nd day on a roll. Volume of > 1.8M is already above its ADV. It announced last week that it had received a letter from the NAZ confirming that it had regained compliance for continued listing,<g> bigcharts.marketwatch.com With some good news it could retest its Apr14 H at $1.82 which is above the ACTAY of $1.42 If it could retest the June2009 H at $3.29 it would be a good % gain from present levels.<g> bigcharts.marketwatch.com On June8 2009 it announced negative results of perifosine on NSCLC. Lately it has identified small molecular compounds that inhibit Erk in the low nanomolar range and that have showed an excellent selectivity profile, since other serine threonine, lipid or tyrosine kinases are not inhibited at concentrations up to 10(micro)M. Studies have revealed an ATP competitive mode of action and the potent inhibition of the cellular downstream target Rsk1 in tumor cells with an IC50 value of 158nM. The lead structure AEZS-131 produces cell cycle arrest in G1 and results in growth inhibition of cancer cells and the combination of AEZS-131 with inhibitors of the PI3K pathway has been considered as a potential synergistic approach. For instance, combining it with AEZS-126.<g> AEZS plans to try it for treating MM & colorectal Cas. It has small LTD, but has been burning its cash at a good clip.<g> Bernard